Brazil's health regulator said Monday it had suspended clinical trials of a Chinese-developed Covid-19 vaccine after an "adverse incident" involving a volunteer recipient, a blow for one of the most advanced vaccine candidates.
The regulator, Anvisa, said in a statement that it had "ruled to interrupt the clinical trial of the CoronaVac vaccine after a serious adverse incident" on October 29.
It said it could not give details on what happened because of privacy regulations, but that such incidents included death, potentially fatal side effects, serious disability, hospitalization, birth defects and other "clinically significant events."
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Stopped Sale Of Products Whose Manufacturing Licences Were Suspended: Patanjali To Supreme Court Chardham Yatra On Hold Amid Rain Alert, Pilgrims Urged Not To Start From Rishikesh Vinicius-less Brazil Lose To 10-Man Uruguay On Penalties In Copa America Quarter-Finals 4 Top Leaders Quit Ajit Pawar's Party In Major Setback After Poll Drubbing 600 Jobs, 25,000 Seekers: Air India Drive Sets Off Stampede Fear In Mumbai Karnataka's 100% Quota Bill For Kannadigas In Private Firms For These Posts Berlin University Invites Applications For Master's Program, Details Here 24 Hours After Terror Attack, Encounter Continues In J&K's Doda Former Sikkim Minister's Body Found In West Bengal Canal Track Latest News Live on NDTV.com and get news updates from India and around the world.